ISB News

Six Years In, ISB’s Innovator Award Program an ‘Unqualified Success’ 

Innovator Award Program ROI

Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

The fifth cycle of ISB’s Innovator Award Program officially wrapped up this week with the principal investigators of the 2021-22 projects delivering their final presentations. In April, three 2022-23 Innovator Award collaborative projects were announced. (See the full list of current and former Innovator awardees and projects here.)   

“The Innovator Award Program has been an unqualified success,” said Dr. Nitin Baliga, ISB senior vice president, director and professor. “We created this program in 2017 to drive innovation at ISB and to award cross-cutting projects that bring people from different labs together. The Innovators Program also provides training for participants in grant writing, the preparation of project materials, leading teams, managing budgets, and other tasks that are important for transitioning into an independent career,” he said.

The metrics of the program are impressive. Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

In 2021, Washington Research Foundation (WRF) pledged $100,000 to ISB to fund the Innovator Award Program, with ISB securing an additional $50,000 from other sources. WRF matched their pledge for the 2022-23 Innovator Award cycle, as well. 

“We thank WRF for their generous support not only for this program, but for their longtime support of ISB,” Baliga said.

WRF has provided more than $2.7 million in grants and pledges, including support that brought microbiome specialist Dr. Sean Gibbons to ISB in 2018.

Learn more about the program here.

The 2021-22 Innovators final presentations were:

Project: Discerning the combinatorial regulatory circuitry of microglial differentiation in Alzheimer’s disease using probabilistic Boolean networks

Lead investigator: Bahar Tercan, Postdoctoral Fellow (Shmulevich lab)

ISB research team and collaborators: Cory Funk (Hood-Price Lab), Boris Aguilar (Shmulevich Lab) and Max Robinson (Hood-Price Lab)

 

Project: SOMA: Joint spatial omics and metabolic function analysis in single tissue section at single cell sensitivity

Lead investigator: Yin Tang, Postdoctoral Fellow (Wei Lab)

ISB research team and collaborators: Guangrong Qin (Shmulevich Lab), David L. Gibbs (Shmulevich Lab), Hanjun Cheng (Wei Lab) and Xiaoyang Ye (Wei Lab)

External collaborator: Raymond S. Yeung, University of Washington

 

Project: Multiparameter profiling of exosomes from body fluids to detect and determine site of infection

Co-lead investigators: Yue Lu, Postdoctoral Fellow (Heath Lab) and Christopher Lausted (Hood-Price Lab)

ISB research team and collaborators: Kai Wang (Hood-Price Lab), Alphonsus Ng (Heath lab) and Inyoul Lee (Hood-Price Lab)

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.